

Summary of status of development and availability of A(H9N2) candidate vaccine viruses^{*}

^{*} Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)

7 November 2011

Candidate vaccine viruses

Parent virus	Clade	Candidate vaccine virus	Type of virus or reassortant	Developing Institute	Available from
A/Hong Kong/1073/99	G1	Wild type	Wild type	NIBSC, UK	NIBSC, UK
A/chicken/Hong Kong/G9/97	Y280/G9	NIBRG-91	Reverse genetics	NIBSC, UK	NIBSC, UK
A/chicken/Hong/G9/97	Y280/G9	IBCDC-2	Classical reassortant	CDC, USA	CDC, USA

Candidate vaccine virus in preparation

Parent virus	Clade	Candidate vaccine virus	Type of virus or reassortant	Developing Institute	Availability
A/Hong Kong/33982/2009	G1	IBCDC-RG26	Reverse genetics	CDC, USA	May 2011

Viruses proposed by WHO for candidate vaccine virus preparation

Parent virus	Clade	Candidate vaccine virus	Type of virus or reassortant	Developing Institute
A/Bangladesh/0994/2011-like	G1		Reverse genetics and conventional	CDC, USA NIBSC, UK

Institutes and contact details for candidate vaccine virus orders and other information:

CDC: Centers for Disease Control and Prevention , Atlanta USA: rdonis@cdc.gov

NIBSC: National Institute for Biological Standards and Control, UK: standards@nibsc.hpa.org.uk

For general enquiries, please contact gisrs-whohq@who.int

For information of other type and subtype candidate vaccine viruses and potency testing reagents, please go to:

<http://www.who.int/influenza/vaccines/virus/en/>